help button home button Am J Pathol ASIP 2008 Summer Academy, Molecular Methcanisms of Human Disease: Injury, Inflammation, and Tissue Repair
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2008.080161 on April 10, 2008

Published online before print April 10, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2008.080161v1
172/5/1171    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Fink, M. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fink, M. P.
(American Journal of Pathology. 2008;172:1171-1173.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.080161

Commentary

Neuropeptide Modulators of High Mobility Group Box 1 Secretion as Potential Therapeutic Agents for Severe Sepsis

Mitchell P. Fink

From Logical Therapeutics, Inc., Waltham, Massachusetts; and the Departments of Critical Care Medicine, Surgery, and Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania

Abstract

This Commentary describes a study suggesting that the endogenous neuropeptides vasoactive intestinal peptide (VIP) and urocortin can improve survival in an animal model of lethal sepsis, possibly through their ability to decrease circulating levels of the cytokine-like protein high mobility group box 1 (HMGB1).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.